Zhan Xiaohui, Liu Yusong, Jannu Asha Jacob, Huang Shaoyang, Ye Bo, Wei Wei, Pandya Pankita H, Ye Xiufen, Pollok Karen E, Renbarger Jamie L, Huang Kun, Zhang Jie
Department of Bioinformatics, School of Basic Medicine, Chongqing Medical University, Chongqing, China.
College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China.
Front Oncol. 2023 Jan 30;13:1080989. doi: 10.3389/fonc.2023.1080989. eCollection 2023.
Rhabdomyosarcoma (RMS) is a soft tissue sarcoma usually originated from skeletal muscle. Currently, RMS classification based on PAX-FOXO1 fusion is widely adopted. However, compared to relatively clear understanding of the tumorigenesis in the fusion-positive RMS, little is known for that in fusion-negative RMS (FN-RMS).
We explored the molecular mechanisms and the driver genes of FN-RMS through frequent gene co-expression network mining (fGCN), differential copy number (CN) and differential expression analyses on multiple RMS transcriptomic datasets.
We obtained 50 fGCN modules, among which five are differentially expressed between different fusion status. A closer look showed 23% of Module 2 genes are concentrated on several cytobands of chromosome 8. Upstream regulators such as MYC, YAP1, TWIST1 were identified for the fGCN modules. Using in a separate dataset we confirmed that, comparing to FP-RMS, 59 Module 2 genes show consistent CN amplification and mRNA overexpression, among which 28 are on the identified chr8 cytobands. Such CN amplification and nearby MYC (also resides on one of the above cytobands) and other upstream regulators (YAP1, TWIST1) may work together to drive FN-RMS tumorigenesis and progression. Up to 43.1% downstream targets of Yap1 and 45.8% of the targets of Myc are differentially expressed in FN-RMS vs. normal comparisons, which also confirmed the driving force of these regulators.
We discovered that copy number amplification of specific cytobands on chr8 and the upstream regulators MYC, YAP1 and TWIST1 work together to affect the downstream gene co-expression and promote FN-RMS tumorigenesis and progression. Our findings provide new insights for FN-RMS tumorigenesis and offer promising targets for precision therapy. Experimental investigation about the functions of identified potential drivers in FN-RMS are in progress.
横纹肌肉瘤(RMS)是一种通常起源于骨骼肌的软组织肉瘤。目前,基于PAX-FOXO1融合的RMS分类被广泛采用。然而,与对融合阳性RMS肿瘤发生机制的相对清晰理解相比,对融合阴性RMS(FN-RMS)的肿瘤发生机制了解甚少。
我们通过对多个RMS转录组数据集进行频繁基因共表达网络挖掘(fGCN)、差异拷贝数(CN)和差异表达分析,探索FN-RMS的分子机制和驱动基因。
我们获得了50个fGCN模块,其中5个在不同融合状态之间存在差异表达。进一步观察发现,模块2中23%的基因集中在8号染色体的几个细胞带。为fGCN模块鉴定了诸如MYC、YAP1、TWIST1等上游调节因子。在另一个数据集中我们证实,与FP-RMS相比,59个模块2基因显示出一致的CN扩增和mRNA过表达,其中28个位于已鉴定的8号染色体细胞带上。这种CN扩增以及附近的MYC(也位于上述细胞带之一)和其他上游调节因子(YAP1、TWIST1)可能共同作用驱动FN-RMS的肿瘤发生和进展。在FN-RMS与正常对照的比较中,高达43.1%的Yap1下游靶标和45.8%的Myc靶标存在差异表达,这也证实了这些调节因子的驱动力。
我们发现8号染色体上特定细胞带的拷贝数扩增以及上游调节因子MYC、YAP1和TWIST1共同作用,影响下游基因共表达,促进FN-RMS的肿瘤发生和进展。我们的发现为FN-RMS的肿瘤发生提供了新的见解,并为精准治疗提供了有前景的靶点。关于已鉴定的FN-RMS潜在驱动因子功能的实验研究正在进行中。